period between 2008-2018. Multiple variables were analyzed related with histopathological study, surgical complications, adjuvant treatments, follow-up and current status of the patients.

**Results** 109 radical hysterectomies were performed for cervical cancer during the study period. Average age is 46.5 years (range 25-76 years). Most of the patients (n = 101) had stage IB1. The mean tumor size is 1.8 cm (0.4-5 cm). In the first 30 days after surgery, 3 fistulas were detected. In 11%, the margins were free of disease, only one patient presented margin involvement. Two patients had a tumor stage greater than IB1 (1 IB2 and 1 IIA2). The mean number of lymph nodes extracted was 19.8, of those being affected 9.9% (n = 12). 18.3% (n = 20) received adjuvant treatment with radiotherapy + concomitant chemotherapy. Of these 13 were for positive lymph nodes. Therefore, the rate of patients who received adjuvant treatment with N0 was 8.3%. We have only had one recurrence in less than two years of follow up (1.9%).

**Conclusion** HUMIC is a reference in gynecological oncology for the province of Las Palmas with trained personnel with exclusive dedication (Q2) and participating in multicenter studies (Q1 3). It has a multidisciplinary tumor board where all patients are presented according to recommendations of scientific societies (Q4-5) before and after surgery (Q6-7). We present a 2.7% urological fistula (Q18 and Q19 <3%) all of them during learning curve and a patient with BMI of 38. We reached a 99.1% rate of free margins of disease (Q10 > 97%). In 2% we found a staging greater than IB1 (Q11 <10%). Pelvic lymphadenectomy or SLN (Sentix) was performed at 100% of the patients (Q13 > 98%). 8.3% received adjuvant treatment with N0 (Q15 <15%). If there is indication, fertility sparing treatment is offered and currently it is performed in our center (Q14 100%). We had a 2-year recurrence rate of 1% (Q12 <10%).

The only indicator we do not reach is the number of cases (minimum Q1 of 15), since our mean is 10 radical hysterectomies per year. Nevertheless, last year we performed 15 surgeries, which, given our geographical location, we think it allows us to continue as a Reference Center.

---

**FERTILITY-SPARING RADICAL TRACHELECTOMY FOR EARLY STAGE CERVICAL CANCER: 12 CASES SERIES AND LITERATURE REVIEW**

N Doan*, T Nguyen, L Ta, L Luong. Oncology Hospital at Ho Chi Minh city, Gynecology Surgery, Ho Chi Minh, Viet Nam

10.1136/ijgc-2021-ESGO.57

**Introduction/Background** Radical tracheectomy is an alternative treatment for preserving fertility in selected patients with early stage cervical cancer. The purpose of this report is to describe our technique of abdominal radical tracheectomy and review the current literature on this procedure.

**Methodology** We reported 12 cases of radical tracheectomy with pelvic lymphadenectomy in The Oncology Hospital of Ho Chi Minh city between 7/2018 and 9/2020.

**Results** The characteristics of the 12 adult patients who underwent radical tracheectomy included stage IB1 disease in all cases, a mean age of 31 years (range, 29-41), and a median estimated blood loss of 100 ml (range, 70-150). Among them, one case was performed by laparoscopic approach. No one needed adjuvant treatment after surgery and all patients resumed normal menstruation postoperatively. All patients remain disease-free at the time of this report. The only remaining uterine blood supply in these patients are the utero-ovarian vessels. There were one postoperative complication. It was one case of cervical stenosis. Transurethral Foley catheters were removed in all cases at postoperative days 02 – 04.

**Conclusion** Radical tracheectomy with pelvic lymphadenectomy is a feasible operation for selected patients with early stage cervical cancer who desire to preserve reproductive function. Menstruation and reproductive function may be preserved after bilateral uterine vessel ligation.

---

**CERVICAL CANCER APPLICATION (CER-CAP): A NEW APP FOR ESTIMATION OF THE LYMPH NODAL RISK INVASION IN PATIENTS WITH EARLY-STAGE CERVICAL CANCER**

B Guan*,† Gaillard, LA Teo-Fortin, V Balaya, M Plante, X Paoletti, L Lécuret, Mathivet. 1Lausanne University Hospital, Lausanne, Switzerland; 2Lausanne University Hospital, Lausanne, Switzerland; 3Institut Curie Hospital, Paris, France; 4Laval University, Québec, Canada; 5Hôtel-Dieu de Québec, Québec, Canada

10.1136/ijgc-2021-ESGO.58

**Introduction/Background** Lymph node status is a major prognostic factor in early-stage cervical cancer. According to the International Federation of Gynecology and Obstetrics (FIGO) 2018 classification, the presence of metastatic lymph node involvement, including the presence of macrometastasis (MAC) or micrometastasis (MIC), is classified as stage IIIC. The recommended treatment is a combination of chemoradiation without complete surgery. Assigning initial staging of patients is therefore essential for the therapeutic management.

**Methodology** We performed a secondary analysis of data from two prospective multicenter trials assessing the role of the sentinel node in the surgical management of cervical cancer (SENTICOL 1 and 2 pooled together in the training dataset). The histological risk factors were included in a multivariable logistic regression model in order to determine the most suitable prediction model. An internal validation of the chosen prediction model was then carried out by a cross validation of the ‘leave one out cross validation’ type. The prediction model implemented into an interactive online application of the ‘Shinyapp’ type. Finally, an external validation was performed with a retrospective cohort of L’Hôtel-Dieu de Québec in Canada.

**Results** Three hundred twenty-one patients participating in Senticol 1 and 2 were included in our training analysis. Among these patients, 280 did not present lymph node invasion (87.2%), 13 presented ITC (4%), 11 presented MIC (3.4%) and 17 MAC (5.3%). Tumor size, presence of lymphovascular space invasion and stromal invasion were included in the prediction model. The Receiver Operating Characteristic (ROC) Curve from this model had an area under the curve (AUC) of 0.79 (95% CI [0.69 – 0.90]). The AUC ROC curve from the cross validation was 0.63. The external validation on the Canadian cohort confirmed a good discrimination of the model with AUC ROC of 0.83.

**Conclusion** This study is the first study of a prediction score for lymph node involvement in early-stage cervical cancer that includes internal and external validation of a prediction score for lymph node involvement in early-stage cervical cancer. The web application is a simple, practical, and modern method of using this prediction score in clinical management.